KRAS and non-small cell lung carcinoma: Emerging targets such as KRAS G12C (~13%) and HER2 (~2–3%) also have FDA-approved therapies in metastatic NSCLC, with early-phase studies evaluating their incorporation into resectable disease management [5,31].